SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The… Read more
Market Cap & Net Worth: SMS Pharmaceuticals Limited (SMSPHARMA)
SMS Pharmaceuticals Limited (NSE:SMSPHARMA) has a market capitalization of $438.18 Million (₹37.95 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #18012 globally and #843 in its home market, demonstrating a 8.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SMS Pharmaceuticals Limited's stock price ₹405.20 by its total outstanding shares 93652030 (93.65 Million).
SMS Pharmaceuticals Limited Market Cap History: 2015 to 2026
SMS Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows growth from $124.50 Million to $438.18 Million (18.02% CAGR).
SMS Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SMS Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
SMS Pharmaceuticals Limited's market cap is 0.04 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.49x
SMS Pharmaceuticals Limited's market cap is 0.49 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $87.98 Million | $6.03 Billion | $408.92 Million | 0.01x | 0.22x |
| 2017 | $108.89 Million | $6.54 Billion | $410.40 Million | 0.02x | 0.27x |
| 2018 | $71.20 Million | $4.61 Billion | $317.50 Million | 0.02x | 0.22x |
| 2019 | $43.16 Million | $4.62 Billion | $400.48 Million | 0.01x | 0.11x |
| 2020 | $126.64 Million | $4.07 Billion | $315.74 Million | 0.03x | 0.40x |
| 2021 | $138.00 Million | $5.61 Billion | $625.27 Million | 0.02x | 0.22x |
| 2022 | $89.22 Million | $5.15 Billion | $622.20 Million | 0.02x | 0.14x |
| 2023 | $128.22 Million | $5.22 Billion | -$70.59 Million | 0.02x | N/A |
| 2024 | $258.29 Million | $7.09 Billion | $498.26 Million | 0.04x | 0.52x |
| 2025 | $335.66 Million | $7.83 Billion | $691.36 Million | 0.04x | 0.49x |
Competitor Companies of SMSPHARMA by Market Capitalization
Companies near SMS Pharmaceuticals Limited in the global market cap rankings as of March 18, 2026.
Key companies related to SMS Pharmaceuticals Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
SMS Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, SMS Pharmaceuticals Limited's market cap moved from $124.50 Million to $ 438.18 Million, with a yearly change of 18.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹438.18 Million | +30.54% |
| 2025 | ₹335.66 Million | +29.96% |
| 2024 | ₹258.29 Million | +101.44% |
| 2023 | ₹128.22 Million | +43.71% |
| 2022 | ₹89.22 Million | -35.35% |
| 2021 | ₹138.00 Million | +8.97% |
| 2020 | ₹126.64 Million | +193.38% |
| 2019 | ₹43.16 Million | -39.37% |
| 2018 | ₹71.20 Million | -34.62% |
| 2017 | ₹108.89 Million | +23.77% |
| 2016 | ₹87.98 Million | -29.33% |
| 2015 | ₹124.50 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of SMS Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $438.18 Million USD |
| MoneyControl | $438.18 Million USD |
| MarketWatch | $438.18 Million USD |
| marketcap.company | $438.18 Million USD |
| Reuters | $438.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.